(Q45945235)

18 December 2017

title

End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. (English)

1 reference

18 December 2017

0 references

0 references

0 references

0 references

Maurizio Bifulco

1

1 reference

18 December 2017

Simona Pisanti

series ordinal

2

1 reference

18 December 2017

publication date

1 July 2009

1 reference

18 December 2017

Nature Reviews Drug Discovery

published in

1 reference

18 December 2017

volume

8

1 reference

18 December 2017

issue

7

1 reference

18 December 2017

page(s)

594

1 reference

18 December 2017

End of the line for cannabinoid receptor 1 as an anti-obesity target?

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD2775-C1

Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2775-C1

Endocannabinoids in endocrine and related tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2775-C1

Overweight, obesity, and cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2775-C1

Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2775-C1

Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2775-C1

31 March 2020

Identifiers

DOI

10.1038/NRD2775-C1

1 reference

18 December 2017

Dimensions Publication ID

1028392434

0 references

1 reference

18 December 2017